Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cadonilimab Combined With Induction Chemotherapy and Definitive Radiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Single-arm Trial (EC-CRT-006)

Next Previous
Trial Profile

Cadonilimab Combined With Induction Chemotherapy and Definitive Radiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Single-arm Trial (EC-CRT-006)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cadonilimab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
  • Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms EC-CRT-006

Most Recent Events

  • 10 Mar 2024 Status changed from not yet recruiting to recruiting.
  • 07 Feb 2024 Planned initiation date changed from 15 Dec 2023 to 28 Feb 2024.
  • 27 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top